In this issue, we are delighted to present state of the art reviews on topics of interest, including: the pathogenesis of SCLC and the multiple aberrant pathways and mutations, leading to its unique biology and clinical features; the meaningful progress, that though slow, has pointed to a number of new targets of interest; the instrumental role of mouse models exploring the Hedgehog and Notch pathways, among others, leading to the development of clinical trials; clinical studies that attempt to target MYC- and FGFR1-amplified SCLC and to disrupt DNA repair pathways to cause apoptosis or to modulate the immune response in SCLC as a treatment modality.
